[go: up one dir, main page]

WO2009047903A1 - チミジンホスホリラーゼ阻害剤を有効成分として含有する炎症性疾患の予防又は治療剤 - Google Patents

チミジンホスホリラーゼ阻害剤を有効成分として含有する炎症性疾患の予防又は治療剤 Download PDF

Info

Publication number
WO2009047903A1
WO2009047903A1 PCT/JP2008/002860 JP2008002860W WO2009047903A1 WO 2009047903 A1 WO2009047903 A1 WO 2009047903A1 JP 2008002860 W JP2008002860 W JP 2008002860W WO 2009047903 A1 WO2009047903 A1 WO 2009047903A1
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory disease
prophylactic
therapeutic agent
active ingredient
phosphorylase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/002860
Other languages
English (en)
French (fr)
Inventor
Kazuki Sakamoto
Yoshikazu Sugimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to CN200880110942A priority Critical patent/CN101820914A/zh
Priority to AU2008310480A priority patent/AU2008310480B2/en
Priority to EP08837483A priority patent/EP2204192A4/en
Priority to CA2701880A priority patent/CA2701880A1/en
Priority to JP2009536926A priority patent/JP5296699B2/ja
Priority to US12/682,670 priority patent/US20100240682A1/en
Publication of WO2009047903A1 publication Critical patent/WO2009047903A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　炎症性疾患の優れた予防又は治療剤の提供。 　チミジンホスホリラーゼ阻害剤を有効成分として含有する炎症性疾患の予防又は治療剤（ただし、チミジンホスホリラーゼ阻害剤が５－クロロ－６－（２－イミノピロリジン－１－イル）メチル－２，４（１Ｈ，３Ｈ）－ピリミジンジオン又はその塩である場合は、炎症性疾患から炎症性腸疾患を除く）。
PCT/JP2008/002860 2007-10-11 2008-10-10 チミジンホスホリラーゼ阻害剤を有効成分として含有する炎症性疾患の予防又は治療剤 Ceased WO2009047903A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN200880110942A CN101820914A (zh) 2007-10-11 2008-10-10 含有胸苷磷酸化酶抑制剂作为有效成分的炎症性疾病的预防或治疗剂
AU2008310480A AU2008310480B2 (en) 2007-10-11 2008-10-10 Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient
EP08837483A EP2204192A4 (en) 2007-10-11 2008-10-10 PROPHYLACTIC OR THERAPEUTIC AGAINST INFLAMMATORY DISEASES WITH THYMIDINE PHOSPHORYLASEINHIBITOR AS AN ACTIVE SUBSTANCE
CA2701880A CA2701880A1 (en) 2007-10-11 2008-10-10 Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient
JP2009536926A JP5296699B2 (ja) 2007-10-11 2008-10-10 チミジンホスホリラーゼ阻害剤を有効成分として含有する炎症性疾患の予防又は治療剤
US12/682,670 US20100240682A1 (en) 2007-10-11 2008-10-10 Phophylactic or therapeutic agent for inflamatory disease comprising thymidine phosphorylase inhibitor as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007265276 2007-10-11
JP2007-265276 2007-10-11

Publications (1)

Publication Number Publication Date
WO2009047903A1 true WO2009047903A1 (ja) 2009-04-16

Family

ID=40549055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002860 Ceased WO2009047903A1 (ja) 2007-10-11 2008-10-10 チミジンホスホリラーゼ阻害剤を有効成分として含有する炎症性疾患の予防又は治療剤

Country Status (9)

Country Link
US (1) US20100240682A1 (ja)
EP (1) EP2204192A4 (ja)
JP (1) JP5296699B2 (ja)
KR (1) KR20100081312A (ja)
CN (1) CN101820914A (ja)
AU (1) AU2008310480B2 (ja)
CA (1) CA2701880A1 (ja)
TW (1) TWI435725B (ja)
WO (1) WO2009047903A1 (ja)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030346A1 (en) * 1995-03-29 1996-10-03 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
WO1998013045A1 (en) * 1996-09-24 1998-04-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
JP2000273044A (ja) 1999-03-23 2000-10-03 Taiho Yakuhin Kogyo Kk 副作用軽減剤
JP2001131075A (ja) 1999-11-05 2001-05-15 Taiho Yakuhin Kogyo Kk 抗ｈｉｖ剤
WO2004111237A1 (en) 2003-04-16 2004-12-23 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR (ECGF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2007122812A1 (ja) * 2006-04-13 2007-11-01 Taiho Pharmaceutical Co., Ltd. 炎症性腸疾患治療薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275988A1 (en) * 2003-09-05 2007-11-29 Schramm Vern L Transition state structure and inhibitors of thymidine phosphorylases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030346A1 (en) * 1995-03-29 1996-10-03 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
JP3088757B2 (ja) 1995-03-29 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤
WO1998013045A1 (en) * 1996-09-24 1998-04-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
JP3088758B2 (ja) 1996-09-24 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体を含有する癌転移抑制剤
JP2000273044A (ja) 1999-03-23 2000-10-03 Taiho Yakuhin Kogyo Kk 副作用軽減剤
JP2001131075A (ja) 1999-11-05 2001-05-15 Taiho Yakuhin Kogyo Kk 抗ｈｉｖ剤
WO2004111237A1 (en) 2003-04-16 2004-12-23 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR (ECGF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2007122812A1 (ja) * 2006-04-13 2007-11-01 Taiho Pharmaceutical Co., Ltd. 炎症性腸疾患治療薬

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BIOL. PHARM. BULL., vol. 19, no. 11, November 1996 (1996-11-01), pages 1407 - 11
BJU INT., vol. 100, no. 4, October 2007 (2007-10-01), pages 935 - 9
CANCER RES., vol. 64, no. 20, 15 October 2004 (2004-10-15), pages 7526 - 32
CANCER SCI., vol. 95, no. 11, November 2004 (2004-11-01), pages 851 - 7
CLIN. CHIM. ACTA., vol. 217, no. 1, September 1993 (1993-09-01), pages 1 - 4
DATABASE BIOSIS BIOSIS; XP008135194, accession no. STN Database accession no. DN: PREV200100362820 *
INT. J. CLIN. ONCOL., vol. 11, no. 4, August 2006 (2006-08-01), pages 297 - 302
J. GASTROENTEROL., vol. 38, no. 3, 2003, pages 229 - 37
J. UROL., vol. 167, no. 1, January 2002 (2002-01-01), pages 347 - 51
MURO, H. ET AL.: "Autocrine induction of gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) and GLS-induced expression of matrix metalloproteinases in rheumatoid arthritis synoviocytes", RHEUMATOLOGY, vol. 38, no. 12, 1999, OXFORD, pages 1195 - 1202, XP008133237 *
NEPHRON CLIN. PRACT., vol. 102, no. 3-4, 2006, pages 133 - 42
SAITO, S. ET AL.: "Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease", J GASTROENTEROL, vol. 38, no. 3, 2003, pages 229 - 37, XP008133005 *
See also references of EP2204192A4 *
UEDA, T. ET AL.: "Over expression of platelet- derived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma", J UROL, vol. 167, no. 1, 2002, pages 347 - 51, XP005543610 *
UEDA, T. ET AL.: "Reduction in bladder platelet-derived endothelial cell growth factor (PD-ECGF/ thymidine phosphorylase (TP) during the oral treatment of interstitial cystitis (IC) using IPD-1151T", JOURNAL OF UROLOGY, vol. 165, no. 5, 2001, pages 66 *
VAN, D.E. ET AL.: "Systemic aspects of interstitial cystitis, immunology and linkage with autoimmune disorders", INT J UROL, vol. 10, 2003, pages S35 - 8, XP008133240 *
WAGURI, Y. ET AL.: "Gliostatin/platelet-derived endothelial cell growth factor as a clinical marker of rheumatoid arthritis and its regulation in fibroblast-like synoviocytes", BR J RHEUMATOL, vol. 36, no. 3, 1997, pages 315 - 21, XP008133239 *

Also Published As

Publication number Publication date
EP2204192A1 (en) 2010-07-07
US20100240682A1 (en) 2010-09-23
KR20100081312A (ko) 2010-07-14
JPWO2009047903A1 (ja) 2011-02-17
CN101820914A (zh) 2010-09-01
AU2008310480A1 (en) 2009-04-16
TW200920375A (en) 2009-05-16
CA2701880A1 (en) 2009-04-16
TWI435725B (zh) 2014-05-01
JP5296699B2 (ja) 2013-09-25
EP2204192A4 (en) 2011-12-21
AU2008310480B2 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
USD681383S1 (en) Blanket
WO2008114800A3 (en) Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007117465A3 (en) Indazole compounds
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2009057079A3 (en) Novel pyrimidine derivatives
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2007136592A3 (en) 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2009018909A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
TW200728307A (en) Novel spirochromanone derivatives
WO2007149907A3 (en) Pyrazoloquinazolinones as parp inhibitors
EP2078721A3 (en) Thieno-pyrimidime compounds having fungicidal activity
WO2007106746A3 (en) Formulations for ecallantide
WO2008025015A3 (en) Epitope-protein scaffolds and their use
WO2007121917A3 (en) Purine derivatives as adenosine receptor activator
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2008155666A3 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
WO2007112913A3 (en) Benzimidazole derivatives
WO2008033757A3 (en) 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880110942.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08837483

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009536926

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2701880

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20107007631

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008310480

Country of ref document: AU

Ref document number: 2008837483

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12682670

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008310480

Country of ref document: AU

Date of ref document: 20081010

Kind code of ref document: A